Licenses BVaraU antiviral agent from Yamsa Shoyu of Japan. BVaraU is being investigated for treating shingles and cold sores caused by the herpes zoster and herpes simplex virus. Squibb filed for an IND in February; clinical trials are expected to begin in the U.S. and Europe in late 1989.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.